The question I posed was their thoughts on immunomodulators that were shown not to have Tocilizumab and Sarilumab's SAE's, like LLMab, and what they're doing to accelerate studies and approvals for this class, given they're variant agnostic.

Of course, no mention... publicity stunt, not a true AMA